Reduction of Doxorubicin-Induced Cardiotoxicity Using
Nanocarriers: A Review

J 2017

Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review

FOJTŮ, Michaela, Jaromír GUMULEC, Tibor STRAČINA, Martina RAUDENSKÁ, Anna SKOTÁKOVÁ et. al.

Základní údaje

Originální název

Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review

Autoři

FOJTŮ, Michaela (203 Česká republika, domácí), Jaromír GUMULEC (203 Česká republika, domácí), Tibor STRAČINA (703 Slovensko, domácí), Martina RAUDENSKÁ (203 Česká republika, domácí), Anna SKOTÁKOVÁ (203 Česká republika, domácí), Markéta VACULOVIČOVÁ (203 Česká republika), Vojtech ADAM (203 Česká republika), Petr BABULA (203 Česká republika, domácí), Marie NOVÁKOVÁ (203 Česká republika, domácí) a Michal MASAŘÍK (203 Česká republika, garant, domácí)

Vydání

Current Drug Metabolism, Sharjah, Bentham Science Publishers B.V. 2017, 1389-2002

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10608 Biochemistry and molecular biology

Stát vydavatele

Spojené arabské emiráty

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.655

Kód RIV

RIV/00216224:14110/17:00097608

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2174/1389200218666170105165444

UT WoS

000399610900006

Klíčová slova anglicky

Doxorubicin; nanoparticles; liposomal; polymeric; protein; gold; cardiotoxicity; nanocarriers

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 3. 2018 12:01, Soňa Böhmová

Anotace

V originále

Background: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet. Objective: This review represents an overall appraisal of studies concerning with the utilization of various doxorubicin-loaded nanoparticles in the cancer treatment with specific emphasis on those studies evaluating their influence on the reduction of heart tissue damage. Conclusion: Introduction of nanoscale drug delivery systems undoubtedly represents nowadays one of the most promising tools for lowering systemic toxicity. Nanoparticles enable to target the therapeutic payload directly towards the tumor tissue, thus leading to the increased accumulation of the drug in the desired tissue and simultaneously protecting surrounding healthy tissues.

Návaznosti

MUNI/A/1365/2015, interní kód MU

Název: Kardiovaskulární systém: od modelu přes terapii k prevenci (Akronym: KAMOTEPRE)

Investor: Masarykova univerzita, Kardiovaskulární systém: od modelu přes terapii k prevenci, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

FOJTŮ, Michaela, Jaromír GUMULEC, Tibor STRAČINA, Martina RAUDENSKÁ, Anna SKOTÁKOVÁ, Markéta VACULOVIČOVÁ, Vojtech ADAM, Petr BABULA, Marie NOVÁKOVÁ a Michal MASAŘÍK. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. Current Drug Metabolism. Sharjah: Bentham Science Publishers B.V., 2017, roč. 18, č. 3, s. 237-263. ISSN 1389-2002. Dostupné z: https://dx.doi.org/10.2174/1389200218666170105165444.

@article{1390003,
   author = {Fojtů, Michaela and Gumulec, Jaromír and Stračina, Tibor and Raudenská, Martina and Skotáková, Anna and Vaculovičová, Markéta and Adam, Vojtech and Babula, Petr and Nováková, Marie and Masařík, Michal},
   article_location = {Sharjah},
   article_number = {3},
   doi = {http://dx.doi.org/10.2174/1389200218666170105165444},
   keywords = {Doxorubicin; nanoparticles; liposomal; polymeric; protein; gold; cardiotoxicity; nanocarriers},
   language = {eng},
   issn = {1389-2002},
   journal = {Current Drug Metabolism},
   title = {Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review},
   volume = {18},
   year = {2017}
}

TY  - JOUR
ID  - 1390003
AU  - Fojtů, Michaela - Gumulec, Jaromír - Stračina, Tibor - Raudenská, Martina - Skotáková, Anna - Vaculovičová, Markéta - Adam, Vojtech - Babula, Petr - Nováková, Marie - Masařík, Michal
PY  - 2017
TI  - Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
JF  - Current Drug Metabolism
VL  - 18
IS  - 3
SP  - 237-263
EP  - 237-263
PB  - Bentham Science Publishers B.V.
SN  - 13892002
KW  - Doxorubicin
KW  - nanoparticles
KW  - liposomal
KW  - polymeric
KW  - protein
KW  - gold
KW  - cardiotoxicity
KW  - nanocarriers
N2  - Background: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by co-administration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet. Objective: This review represents an overall appraisal of studies concerning with the utilization of various doxorubicin-loaded nanoparticles in the cancer treatment with specific emphasis on those studies evaluating their influence on the reduction of heart tissue damage. Conclusion: Introduction of nanoscale drug delivery systems undoubtedly represents nowadays one of the most promising tools for lowering systemic toxicity. Nanoparticles enable to target the therapeutic payload directly towards the tumor tissue, thus leading to the increased accumulation of the drug in the desired tissue and simultaneously protecting surrounding healthy tissues.
ER  -

FOJTŮ, Michaela, Jaromír GUMULEC, Tibor STRAČINA, Martina RAUDENSKÁ, Anna SKOTÁKOVÁ, Markéta VACULOVIČOVÁ, Vojtech ADAM, Petr BABULA, Marie NOVÁKOVÁ a Michal MASAŘÍK. Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review. \textit{Current Drug Metabolism}. Sharjah: Bentham Science Publishers B.V., 2017, roč.~18, č.~3, s.~237-263. ISSN~1389-2002. Dostupné z: https://dx.doi.org/10.2174/1389200218666170105165444.

Podrobný výpis o publikaci